1. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy

   • Chuan Liu
   • Guangwei Zhang
   • Ti Wen

   Review Article 05 November 2021 Pages: 1549 - 1567

   

2. Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice

   • Xiaoxiao Jin
   • Xiaotao Liu
   • Chuanlai Shen

   Original Article 01 November 2021 Pages: 1569 - 1582

   

3. TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer

   • Luciana Gneo
   • Nagy Rizkalla
   • Gary Middleton

   Original Article Open access 02 November 2021 Pages: 1583 - 1596

   

4. Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy

   • Luya Cai
   • Xuedan Du
   • Wenfeng Li

   Original Article Open access 03 November 2021 Pages: 1597 - 1609

   

5. Redirecting host preexisting influenza A virus immunity for cancer immunotherapy

   • Bharat K. R. Chaganty
   • Songbo Qiu
   • Zhen Fan

   Original Article 03 November 2021 Pages: 1611 - 1623

   

6. Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study

   • Xiangling Chu
   • Huiping Qiang
   • Chunxia Su

   Original Article 07 November 2021 Pages: 1625 - 1631

   

7. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis

   • Jun-shuai Xue
   • Hui Liu
   • Tao Li

   Original Article 08 November 2021 Pages: 1633 - 1644

   

8. Distribution, phenotype, functional and clinical relevance of CD8⁺CD103⁺ tissue-resident memory T cells in human gastric cancer

   • Yang Shen
   • Xiao-long Li
   • Liu-sheng Peng

   Original Article 12 November 2021 Pages: 1645 - 1654

   

9. Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells

   • Trefa M. Abdullah
   • Jacqueline Whatmore
   • Paul Eggleton

   Original Article Open access 20 November 2021 Pages: 1655 - 1669

   

10. Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells

    • Grace Lee
    • Sheela Karunanithi
    • David Wald

    Original Article 23 November 2021 Pages: 1671 - 1680

    

11. Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy

    • Qiaoyun Tan
    • Liyuan Dai
    • Yuankai Shi

    Original Article 24 November 2021 Pages: 1681 - 1691

    

12. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study

    • Wenxian Wang
    • Xiaodong Gu
    • Zhengbo Song

    Original Article 24 November 2021 Pages: 1693 - 1703

    

13. Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens

    • Gerulf Hänel
    • Caroline Angerer
    • Marion Subklewe

    Original Article Open access 25 November 2021 Pages: 1705 - 1718

    

14. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study

    • Geoffroy Bilger
    • Nicolas Girard
    • Marie Ange Massiani

    Original Article 25 November 2021 Pages: 1719 - 1731

    

15. Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway

    • Tao Lu
    • Ming Li
    • Lijie Tan

    Original Article 27 November 2021 Pages: 1733 - 1746

    

16. Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

    • Mathilde Bureau
    • Thierry Chatellier
    • Elvire Pons-Tostivint

    Original Article 28 November 2021 Pages: 1747 - 1756

    

17. Identification of prognostic genes in the pancreatic adenocarcinoma immune microenvironment by integrated bioinformatics analysis

    • Haolan Wang
    • Liqing Lu
    • Yongheng Chen

    Original Article 02 December 2021 Pages: 1757 - 1769

    

18. Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies

    • Audrey Page
    • Emilie Laurent
    • Floriane Fusil

    Research Report Open access 08 November 2021 Pages: 1771 - 1775

    

19. Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy

    • Matteo Bellone
    • Marco Bregni
    • Mario P. Colombo

    Letter to the Editors 09 November 2021 Pages: 1777 - 1786

20. Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15–16, 2020

    • Matteo Bellone
    • Arianna Brevi
    • Mario Paolo Colombo

    Letter to the Editors 16 January 2022 Pages: 1787 - 1794